# Who are Alnylam Pharmaceuticals's customers? Who does Alnylam Pharmaceuticals earn revenue from?
Canonical: https://valuechain.wiki/alnylam-pharmaceuticals · Facet: customers · Updated: 2026-10-12T17:27:00.393+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: Alnylam Pharmaceuticals's confirmed revenue counterparties include Regeneron Pharmaceuticals plus 2 undisclosed/aggregate relationships. Per the valuechain.wiki graph: 3 revenue edges, backed by 4 dated sources, 1 of them primary filings (as of 2026-10-12).

### 글로벌 환자·의료기관 (high)
- metric: Amount $1.2B · Q2 2026 · Global net product revenue
- note: Alnylam sells AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO in the U.S., Europe and other markets. FY2025 net product revenue was $2.987 billion and Q2 2026 net product revenue was $1.172 billion.
- [confirms] Alnylam Pharmaceuticals (EN, ir, published 2026-07-30) https://investors.alnylam.com/press-release?id=ddc78e15-7847-4066-8fdb-3562023a60f4: "Q2 2026 global net product revenue was $1.172 billion, up 74% year over year."
- [confirms] SEC EDGAR (EN, filing, published 2026-02-12) https://www.sec.gov/Archives/edgar/data/1178670/000162828026007497/alny-20251231.htm: "FY2025 net product revenue was $2.986549 billion."

### Blackstone (high)  → /blackstone.md
- metric: Amount $1B · 2020; rights reverified Q2 2026 · Consideration for 50% of future Leqvio royalties and 75% of commercial milestone rights
- note: Alnylam sold Blackstone 50% of future Leqvio royalties and 75% of commercial milestones for $1 billion in 2020, and continued to disclose the rights and related liability in Q2 2026.
- [confirms] SEC EDGAR (EN, filing, published 2026-07-30) https://www.sec.gov/Archives/edgar/data/1178670/000117867026000062/alny-20260630.htm: "Alnylam disclosed that Blackstone acquired 50% of Leqvio royalties and 75% of commercial milestones and that related current and non-current liabilities remained recognized at June 30, 2026."
- [confirms] SEC EDGAR (EN, filing, published 2026-02-12) https://www.sec.gov/Archives/edgar/data/1178670/000162828026007497/alny-20251231.htm: "A Blackstone affiliate paid $1.0 billion for 50% of Leqvio royalties and 75% of commercial milestones."
- [mentions] Novartis (EN, ir, published 2026-01-28) https://www.novartis.com/investors/financial-data/product-sales: "Novartis reported $1.198 billion of Leqvio net sales in 2025, up 59% year over year."
- [mentions] Yonhap Infomax (KO, news, published 2020-04-14) https://news.einfomax.co.kr/news/articleView.html?idxno=4082972: "Yonhap Infomax reported Blackstone’s $2 billion strategic financing collaboration with Alnylam."

### 로슈 (high)
- metric: Amount $395M · FY2025 · Revenue from the Roche collaboration
- note: Alnylam recognizes upfront, milestone and R&D revenue from its zilebesiran collaboration with Roche. FY2025 Roche collaboration revenue was $394.881 million.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-12) https://www.sec.gov/Archives/edgar/data/1178670/000162828026007497/alny-20251231.htm: "FY2025 Roche collaboration revenue was $394.881 million."
- [mentions] Eugene Investment & Securities (KO, research, published 2024-02-15) https://www.paxnet.co.kr/WWW/data/researchCenter/attach/20240215110745467.pdf: "Eugene Investment & Securities identifies Roche and Alnylam as co-developers of zilebesiran."

### 리제네론 (high)  → /regeneron-pharmaceuticals.md
- metric: Amount $114M · FY2025 · Revenue from the Regeneron collaboration
- note: Alnylam receives research funding and milestone revenue from its RNAi collaboration and licenses with Regeneron. FY2025 Regeneron collaboration revenue was $113.957 million.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-12) https://www.sec.gov/Archives/edgar/data/1178670/000162828026007497/alny-20251231.htm: "FY2025 Regeneron collaboration revenue was $113.957 million."
- [mentions] Korea Health Industry Development Institute (KO, analysis, published 2021-05-17) https://www.khidi.or.kr/kps/relativeInfo/view?boardKind=NOTICE&linkId=48862147&menuId=MENU01671&no1=&no2=8167&pageNum=48&referenceMenuId=MENU01816&rowCnt=10&schText=&schType=0: "KHIDI describes the Alnylam-Regeneron RNAi development partnership."

Reverse side: https://valuechain.wiki/alnylam-pharmaceuticals/suppliers.md · Ripple: https://valuechain.wiki/alnylam-pharmaceuticals/ripple.md

---
Full node: https://valuechain.wiki/alnylam-pharmaceuticals.md · JSON: https://valuechain.wiki/alnylam-pharmaceuticals.json